200626-61-5
基本信息
ITSA-1(ITSA1)
IFLAB-BB F0451-3184
1-(2,4-Dichlorobenzoyl)-1H-benzotriazole
BENZOTRIAZOL-1-YL-(2,4-DICHLORO-PHENYL)-METHANONE
Methanone, 1H-benzotriazol-1-yl(2,4-dichlorophenyl)-
物理化学性质
熔点 | 119-121°C |
储存条件 | Inert atmosphere,2-8°C |
溶解度 | 二甲基亚砜:28mg/mL |
形态 | 固体 |
颜色 | 白色至灰白色 |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H302 |
防范说明 | P264-P270-P301+P312-P330-P501 |
危险品标志 | Xn |
危险类别码 | 22 |
WGK Germany | 3 |
常见问题列表
HDAC
|
ITSA1 (50 μM; A549 cells) treatment serves to revert the TSA-arrested population to a normal cell cycle distribution. ITSA1 is also able to effect cell cycle rescue over longer duration.
ITSA1 (50 μM; 5 hours; A549 cells) treatment reduces the number of apoptosis in TSA-treated cells.
ITSA1 (50 μM; 2 hours; A549 and murine ES cells cells) treatment suppresses TSA-induced histone acetylation. Importantly, suppression of acetylation levels is only observable when ITSA1 is added concurrent with or post TSA treatment.
ITSA1 (50 μM; 30 minutes; murine ES cells cells) suppresses TSA-activated transcription in murine ES cells.
Cell Cycle Analysis
Cell Line: | Murine ES cells |
Concentration: | 50 μM |
Incubation Time: | |
Result: | Served to revert the TSA-arrested population to a normal cell cycle distribution. |
Apoptosis Analysis
Cell Line: | A549 cells |
Concentration: | 50 μM |
Incubation Time: | 5 hours |
Result: | Reduced the number of apoptosis. |
Western Blot Analysis
Cell Line: | A549 and murine ES cells |
Concentration: | 50 μM |
Incubation Time: | 2 hours |
Result: | Reduced histone acetylation to the baseline level. |
RT-PCR
Cell Line: | Murine ES cells |
Concentration: | 50 μM |
Incubation Time: | 30 minutes |
Result: | Suppressed TSA-activated transcription. |
ITSA-1 (0.5 mg/kg; intraperitoneal injection; 3 times/week; for 8 weeks; CBS +/− mice) treatment balances deacetylation activity and suppresses IL-6 and TNF-α expression and thereby attenuated histone acetylationdependent infammatory signaling.
Animal Model: | CBS +/− mice |
Dosage: | 0.5 mg/kg |
Administration: | Intraperitoneal injection; 3 times/week; for 8 weeks |
Result: | Balanced deacetylation activity and suppressed IL-6 and TNF-α expression. |